Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

• This invention relates generally to new compounds of the formula (I), to pharmaceutical compositions and to methods of treating diseases and conditions by administration of such compounds to a patient in need thereof.
• Type 1 diabetes generally results from the body's failure to produce insulin.
• Type 2 diabetes is the more prevalent type of diabetes and generally results from insulin resistance combined with a relative insulin deficiency. Additionally, there are millions of Americans who can be said to have prediabetes, that is, higher than normal blood glucose levels but not yet high enough to be diagnosed with Type 2 diabetes.
• Type 2 diabetes is characterized by fasting and postprandial hyperglycemia and by relative insulin insufficiency. Hyperglycemia may cause long-term microvascular and macrovascular complications, such as nephropathy, neuropathy, retinopathy, and peripheral vascular disease. In addition, Type 2 diabetes is a comorbid disease that frequently compounds hyperlipidemia, atherosclerosis and hypertension. Hyperlipidemia is a primary risk factor for cardiovascular disease due to atherosclerosis. Obesity is a well known common risk factor for the development of atherosclerosis, stroke, hypertension and Type 2 diabetes. Type 2 diabetes causes significant morbidity and mortality at considerable expense to patients, their families and society.
• Type 2 diabetes worldwide is increasing such that Type 2 diabetes is now considered to be a worldwide epidemic.
• a number of therapies for the treatment of Type II diabetes are in use.
• a change in diet along with an increase in exercise and weight loss is considered a first line of treatment.
• this may not result in sufficient control of blood glucose levels resulting in the use of medications to help control glucose levels.
• These medications include insulin, sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, alpha-glucosidase inhibitors, amylin analogs and incretin mimetics.
• These medications may be used singly or in combination and may result in reduced glucose levels.
• GPRl 19 is a class 1 G-protein-coupled receptor which has received attention due to evidence that modulation of the GRPl 19 receptor may produce favorable effects on glucose homeostasis, food intake, body weight gain and ⁇ -cell preservation, any or all of which effects may be useful in the treatment of both diabetes and obesity ⁇ Br. J. Pharm. 2007 1-6).
• the GPRl 19 receptor and iso forms have been identified in mammalian species including human, rat, mouse, hamster, chimpanzee, rhesus monkey, cattle and dog.
• the pancreas has been identified as the major site of mRNA expression in the human, with some expression also seen in the gastrointestinal tract.
• the expression of GPRl 19 in the pancreas and particularly in the pancreatic ⁇ -cells led to the hypothesis that the GPRl 19 receptor could have effects upon insulin secretion.
• GPRl 19 knockout animals have shown that both insulin and incretin secretion induced by GPRl 19 agonists are dependent upon GPRl 19 receptor. In addition, it has been shown that GPRl 19 agonists decrease food intake resulting in weight loss in Sprague Dawley rats. Taken together, GPRl 19 is a novel mechanism by which glycemic control may be facilitated with the added benefit of weight loss.
• this invention is generally directed to new compounds, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same. More specifically, the new compounds are useful as GPRl 19 receptor agonists.
• the present invention relates to a compound of the following general formula (I):
• the present invention relates to processes for preparing a compound of general formula (I) and to new intermediate compounds in these processes.
• a further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.
• the compounds of this invention may have utility over a wide range of therapeutic applications, and may be used to treat a variety of diseases and conditions in both men and women, as well as a mammal in general (also referred to herein as a "patient"). For example, such conditions include diabetes and obesity.
• the compounds of the present invention may treat these conditions through effects on glucose homeostasis, food intake, body weight gain and beta-cell preservation.
• this invention relates to a method for treating diseases or conditions which are mediated by modulating the activity of GPRl 19 enzyme(s) in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to a patient.
• a method for treating a metabolic disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• the methods of this invention include administering an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition, to a patient in need thereof.
• this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more pharmaceutically acceptable carriers and/or diluents.
• Compounds of the present invention may be administered along with additional agents, for example to help lower glucose levels.
• Additional therapeutic agents which may be used in conjunction with a compound of the current invention include insulin, sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, alpha- glucosidase inhibitors, amylin analogs and incretin mimetics.
• this invention relates to a method for treating a disease or condition mediated by modulating the activity of GPRl 19 in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents.
• this invention relates to a use of a compound of the general formula (I) in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by modulating the activity of GPRl 19.
• this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) and one or more additional therapeutic agents, optionally together with one or more pharmaceutically acceptable carriers and/or diluents.
• the present invention is directed generally to compounds useful as GPRl 19 receptor agonists.
• the compounds of this invention have the following structure (I):
• X 1 , X 2 , X 3 , and X 4 are independently -N- or -C(R 5 )-; Y 1 and Y 2 are independently -N- or -C(R 3 )-; A is -O- or -N(R 7 )-;
• R 2 at each occurrence is independently Ci_ 4 alkyl, F, hydroxy, or Ci_ 4 alkyl-0-;
• R 3 at each occurrence is independently H, halogen, CN, Ci_ 4 alkyl, Ci_ 4 alkyl-0- or Ci_
• R 4 at each occurrence is independently H, halogen, or Ci_ 4 alkyl;
• R 6 is R Alk , heterocycle, heterocycle-Ci_ 3 -alkyl or aryl, wherein each R Alk , alkyl, heterocycle and aryl is optionally substituted with 1-4 substituents independently of each other selected from R 9 ;
• R 7 at each occurrence is independently H or R Alk wherein each R Alk is optionally substituted with 1-4 substituents independently of each other selected from halogen, hydroxy, -N(R 8 ) 2 , d_ 4 alkyl-O-, and -CO 2 R 8 ;
• R 8 at each occurrence is independently H or Ci_ 4 alkyl;
• R Alk at each occurence is independently C ⁇ -alkyl, C 2 _6-alkenyl, C 2 _6-alkynyl, C 3-8 - cycloalkyl, C 3 - 8 -cycloalkyl-Ci_ 3 -alkyl, C 4 - 8 -cycloalkenyl or C 4 - 8 -cycloalkenyl-Ci_ 3 -alkyl; m is O, 1, or 2; n is O, 1, or 2; p is 0 or 1 ; and q is 0, 1, or 2, including any tautomers and stereoisomers thereof,
• the groups, residues, and substituents particularly X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and the indexes, particularly m, n, p, q, are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound, as for example R Alk , R 6 , R 7 , R 8 , R 9 , they may have the same or different meanings. Some preferred meanings of individual groups and substituents of the compounds according to the invention will be given hereinafter. Any and each of these definitions may be combined with each other.
• the groups X 1 , X 2 , X 3 , and X 4 are independently -N-, -CH- or -C(R 5 )-.
• the groups X 1 , X 2 , X 3 , and X 4 are independently -N-, -CH- or -C(R 5 )-, wherein at least one of X 1 , X 2 , X 3 , and X 4 is -C(R 5 )-, wherein R 5 is defined as hereinbefore and hereinbefore, but does not denote hydrogen.
• the groups X 1 , X 2 , X 3 , and X 4 are independently -CH- or -C(R 5 )-, wherein R 5 is defined as hereinbefore and hereinbefore, but does not denote hydrogen.
• the groups X 1 , X 2 , X 3 , and X 4 are independently -CH- or -C(R 5 )-, wherein at least one of X 1 , X 2 , X 3 , and X 4 is -C(R 5 )-, wherein R 5 is defined as hereinbefore and hereinbefore, but does not denote hydrogen.
• X-E3 the groups X 1 , X 3 , and X 4 are -CH- and X 2 is -C(R 5 )- wherein R 5 is defined as hereinbefore and hereinbefore, but does not denote hydrogen.
• Y-El the groups Y 1 and Y 2 are independently -N- or -C(R 3 )-.
• Y-E2 the group Y 1 is -C(R 31 )- and Y 2 is N or -C(R 32 )-, wherein R 31 and R 32 are defined as R 3 .
• R 31 and R 32 independently of each other denote H, F, CN, Ci_ 3 -alkyl or Ci_ 3 -alkyl-O-.
• Y-E3 the group Y 1 is -C(R 31 )- and Y 2 is N, wherein R 31 is defined as R 3 .
• R 31 denotes H, F, CN, Ci_3- alkyl or Ci_ 3 -alkyl-O-, in particular H, F, CH 3 , -O-CH 3 .
• R 31 denotes H.
• the group A denotes -O- or -N(R 7 )-.
• the group A denotes -O-.
• the group A denotes -NR 7 -, wherein R 7 denotes H, Ci_ 4 -alkyl, C 3 _ 4 -alkenyl, Ci_ 3 -alkyl-O-Ci_ 3 -alkyl.
• the group A denotes -NR 7 -, wherein R 7 denotes H, methyl, ethyl, sec-butyl, allyl, CH 3 -O-CH 2 -.
• the index p is 0 or 1 and the index q is 0, 1 or 2.
• the index p is 1 and the index q is 1.
• the index p is 0 and the index q is 0.
• n 0, 1 or 2.
• the index m is 1 and the index n is 0.
• R*-E2 the group R 1 denotes -CO 2 R 6 ,
• R 1 -E4a the group R 1 is selected from
• R 1 -E4b the group R 1 is selected from
• R is benzyl, which is optionally substituted by 1 to 5 F- atoms.
• R 2 -E1 the group R 2 denotes at each occurrence independently Ci_ 4 alkyl, F, hydroxy or Ci_ 4 alkyl-O-.
• R 3 -E1 the group R 3 denotes H, halogen, CN, Ci_ 4 alkyl, C 1- 4 alkyl-O-, or Ci_ 4 alkyl-S-.
• R 3 -E2 the group R 3 denotes H, Cl, methyl, methylthio.
• R 3 -E3 the group R 3 denotes H.
• R 4 I According to an embodiment R 4 -E1 the group R 4 denotes at each occurrence independently H, halogen, or Ci_ 4 alkyl.
• R 6 -E1 the group R 6 denotes Ci_ 6 -alkyl, C 3 _ 7 -cycloalkyl, C 3 _ 7 - cycloalkyl-Ci_ 3 -alkyl, heterocycle, heterocycle-Ci_ 3 -alkyl, wherein each of the beforementioned group is optionally substituted with 1 to 4 substituents independently of each other selected from R 9 .
• R 6 -E2 the group R 6 denotes Ci_ 4 -alkyl, C 3 _ 6 -cycloalkyl, C 3 _ 6 - cycloalkyl-Ci_ 3 -alkyl, wherein each of the beforementioned group is optionally substituted with 1 to 4 substituents independently of each other selected from R 9 , in particular selected from F and Ci_3-alkyl-O-.
• R 6 -E3 the group R 6 denotes i-propyl, sec-butyl, tert-butyl, cyclopropyl, cycloproyl-methyl-, all of which optionally substituted with one or more F, Ci-3-alkyl-O-,
• R 6 -E4 the group R 6 denotes heterocycle which is selected from azetidinyl, pyrrolidinyl, piperidinyl and azepanyl, wherein the heterocycle group is optionally substituted with 1 to 4 substituents independently of each other selected from R 9 , in particular selected from Ci_ 3 -alkyl and phenyl-Ci_ 3 -alkyl, wherein the phenyl ring is optionally substituted with 1-4 substituents independently of each other selected from F, Ci-3-alkyl-, Ci_ 3 -alkyl-O-.
• R 7 -E1 the group R 7 denotes H or R Alk wherein said R Alk is optionally substituted with 1-4 substituents independently of each other selected from halogen, hydroxy, -N(R 8 ) 2 , d_ 4 alkoxy, and -CO 2 R 8 ;
• R 7 -E2 the group R 7 denotes H, Ci_ 4 -alkyl, C 3 - 4 -alkenyl, Ci_ 3 - alkyl-O-Ci. 3 -alkyl.
• R 7 -E2a the group R 7 denotes H, Ci_ 4 -alkyl, C 3 _ 4 -alkenyl.
• R 8 -E1 the group R 8 denotes H or Ci_ 4 alkyl.
• R 9 -E1 the group R 9 denotes cyano, hydroxy, Ci_ 6 alkyl, aryl, aryl-Ci.3-alkyl, heterocycle, halogen, oxo, Ci_ 4 haloalkyl, -NO 2 , -C(O)H, -CO 2 R 8 ,
• each alkyl, aryl and heterocycle is optionally substituted with 1-4 substituent independently of each other selected from halogen, hydroxy, -N(R 8 )2, Ci_4alkoxy, -NR 7 CO 2 R 7 , -NR 7 SO 2 R 7 , and -CO 2 R 8 .
• R Alk -El the group R Alk is selected from the group consisting of Ci_ 6 -alkyl, C 2 - 6 -alkenyl, C 2 - 6 -alkynyl, C 3 _ 8 -cycloalkyl, C 3 _ 8 -cycloalkyl-Ci_ 3 -alkyl, C 4 - S - cycloalkenyl or C 4 _ 8 -cycloalkenyl-Ci_ 3 -alkyl.
• R Alk -E2 the group R Alk is selected from the group consisting of d- 6 -alkyl, C 3 - 7 -cycloalkyl or C 3 - 7 -cycloalkyl-Ci_ 3 -alkyl.
• R Alk -E3 the group R Alk is selected from the group consisting of Ci_4-alkyl, C3-6-cycloalkyl or C3-6-cycloalkyl-CH 2 -.
• X 1 , X 3 , and X 4 of structure (I) are
• Structure (III) shows an embodiment of structure (II) where Y 1 is -C(R 3 )- and R 3 is H, and Y 2 is N.
• m and n are 0, p and q are 1, and R 1 is -CO 2 R 6 as shown in structure (IV).
• A is -N(R 7 )- and Y 1 and Y 2 are -C(R 3 )- where R 3 is H as shown in structure (V).
• m and n are 0, p and q are 1 , and A is NR as shown in structure (VI).
• Y 1 is -C(R 3 )- where R 3 is H, and R 1 is -CO 2 R 6 as shown in structure (VII).
• r is 0 to 4, in particular r is 1 ;
• X r 1 1 , and X 4 are selected from an embodiment X-El, X-EIa, X-E2, X-E2a or X-E3;
• R 1 is selected from an embodiment R 1 -El, R ! -E2, R'-E ⁇ , R'-E ⁇ a, R ! -E4a or R ! -E4b;
• R 2 is selected from an embodiment R 1 -El;
• R 3 is selected from an embodiment R 3 -E1, R 3 -E2 or R 3 -E3;
• R 31 is selected from the definitions of the group R 3 as described in R 3 -E1, R 3 -E2 or R 3 -E3 or R 31 denotes H, F, CN, Ci_ 3 -alkyl or Ci_ 3 -alkyl-O-.
• R 4 is selected from an embodiment R 4 -E1; and
• R is selected from an embodiment R -El, r R> 5 -E2 or R -E3;
• R 6 is selected from an embodiment R 6 -E1, R 6 -E2, R 6 -E3 or R 6 -E4;
• R 7 is selected from an embodiment R 7 -E1 or R 7 -E2;
• n are selected from an embodiment mn-El or mn-E2;
• p, q are selected from an embodiment pq-El, pq-E2 or pq-E3.
• m is O, 1 or 2 , preferably m is 0, and r is 0, 1 or 2, preferably r is 1, and R 31 is selected from the definitions of the R 3 -E1 or R 31 denotes H, F, CN, C 1-3 - alkyl or Ci_ 3 -alkyl-O-, or R 31 denotes H;
• the compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples.
• the compounds of structure (I) above may be made by the following reaction schemes, wherein all substituents are as defined above unless indicated otherwise.
• the compounds are prepared by O or N-arylation of a cyclic amino alcohol or amine with a dichloroheteroaryl (typically by nucleophilic aromatic displacement of a chloride in presence of a base), followed by reaction of the mono heteroaryl chloride obtained with indoline (either by palladium catalyzed coupling or nucleophilic displacement in presence of a base).
• a dichloroheteroaryl typically by nucleophilic aromatic displacement of a chloride in presence of a base
• indoline either by palladium catalyzed coupling or nucleophilic displacement in presence of a base.
• the compounds can also be prepared by reaction of the indoline with the dichloroheteroaryl first (by palladium catalyzed coupling or nucleophilic displacement in presence of a base), followed by O or N-arylation of a cyclic amino alcohol or amine with the monochloroheteroaryl obtained (typically by nucleophilic aromatic displacement in presence of a base).
• R 1 is a protecting group such as Boc or benzyl
• the amine can be deprotected (typically with TFA for Boc and AceCl or hydrogenation for benzyl) and the amine further derivatized (for example by alkylation).
• compound(s) according to this invention denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates of such tautomers, stereoisomers and salts thereof.
• treatment and “treating” embrace both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment.
• treatment and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form.
• Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease.
• compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
• treatment and “treating” comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
• this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.
• terapéuticaally effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.
• modulated or “modulating”, or “modulate(s)", as used herein, unless otherwise indicated, refers to the modulation of the activity of the GPRl 19 enzyme(s) with one or more compounds of the present invention.
• mediated refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.
• substituted means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.
• each X, Y and Z group is optionally substituted with
• each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined.
• R ex denotes H, Ci_3-alkyl, C3_6-cycloalkyl, C3_6- cycloalkyl-Ci_ 3 -alkyl or Ci_ 3 -alkyl-O-, wherein each alkyl group is optionally substituted with one or more L ex .” or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e.
• the alkyl moiety may be substituted with L ex as defined.
• Ci_6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
• the last named subgroup is the radical attachment point, for example, the substituent "aryl-Ci_ 3 -alkyl-" means an aryl group which is bound to a Ci_ 3 -alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
• the numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
• 3-carboxypropyl-group represents the following substituent:
• oxo denotes an 0-atom which replaces two H-atoms and which is linked to the respective atom via a double bond.
• a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc ..) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• such salts include acetates, ascorbates, benzenesulfonates, benzoates, besylates, bicarbonates, bitartrates, bromides/hydrobromides, Ca-edetates/edetates, camsylates, carbonates, chlorides/hydrochlorides, citrates, edisylates, ethane disulfonates, estolates esylates, fumarates, gluceptates, gluconates, glutamates, glycolates, glycollylarsnilates, hexylresorcinates, hydrabamines, hydroxymaleates, hydroxynaphthoates, iodides, isothionates, lactates, lactobionates, malates, maleates, mandelates, methanesulfonates, mesylates, methylbromides, methylnitrates, methylsulfates, mucates
• salts can be formed with cations from metals like aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like, (also see Pharmaceutical salts, Birge, S.M. et al, J. Pharm. Sci., (1977), 66, 1-19).
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention e.g. trifluoro acetate salts
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
• halogen generally denotes fluorine, chlorine, bromine and iodine.
• Alkyl The term "Ci_ n -alkyl", wherein n is an integer from 2 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms.
• Ci_ 5 -alkyl embraces the radicals H 3 C-, H 3 C-CH 2 -, H 3 C-CH 2 -CH 2 -, H 3 C-CH(CH 3 )-, H 3 C-CH 2 -CH 2 -CH 2 -, H 3 C- CH 2 -CH(CH 3 )-, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-C(CH 3 ) 2 -, H 3 C-CH 2 -CH 2 -CH 2 -CH 2 -, H 3 C- CH 2 -CH 2 -CH(CH 3 )-, H 3 C-CH 2 -CH(CHs)-CH 2 -, H 3 C-CH(CHs)-CH 2 -, H 3 C-CH(CHs)-CH 2 -CH 2 -, H 3 C-CH 2 - C(CHs) 2 -CH 2 -, H 3 C-CH 2 - C(CHs) 2 -CH 2 -, H 3 C
• alkoxy means an alkyl moiety attached through an oxygen bridge (i.e., alkyl-O-) and includes groups such as methoxy and ethoxy.
• alkylthio means an alkyl moiety attached through a sulfur bridge (i.e., alkyl-S-) and includes groups such as methylthio and ethylthio.
• Alkylene The term "Ci_ n -alkylene" wherein n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms.
• Ci_ 4 -alkylene includes -(CH 2 )-, -(CH 2 -CH 2 )-, -(CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 )-, -(C(CHs) 2 )-, - (CH(CH 2 CH 3 ))-, -(CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 ))-, -(CH 2 -CH 2 -CH 2 -CH 2 )-, -(CH 2 - CH 2 -CH(CH 3 ))-, -(CH(CH 3 )-CH 2 -CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 )-, -(CH 2 -C(CH 3 ) 2 )-, -(C (CH 3 ) 2 -, -(
• Alkenyl The term "C 2 _ n -alkenyl", is used for a group as defined in the definition for
• Ci_ n -alkyl with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
• C 2 _ n -alkenylene is used for a group as defined in the definition for "Ci_ n -alkylene” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
• C 2 _ n -alkynyl is used for a group as defined in the definition for "Ci_ n -alkyr with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
• C2-3-alkynyl includes -C ⁇ CH, -C ⁇ C-CH 3 , -CH 2 -C ⁇ CH.
• Alkynylene The term "C2- n -alkynylene" is used for a group as defined in the definition for
• Ci_ n -alkylene with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
• C 2-3 - alkynylene includes -C ⁇ C-, -C ⁇ C-CH 2 -, -CH 2 -C ⁇ C-.
• Carbocyclyl as used either alone or in combination with another radical, means a mono- or multi-ring ring structure consisting only of carbon containing between one and four rings wherein such rings may be attached together in a pendent manner or may be fused.
• carrier refers to fully saturated and aromatic ring systems and partially saturated ring systems.
• carrier additionally encompasses spiro systems, and bridged systems.
• Cs- n -cycloalkyl wherein n is an integer 4 to n, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms.
• C3_7-cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
• Cycloalkenyl The term "Cs- n -cycloalkenyl", wherein n is an integer 3 to n, either alone or in combination with another radical, denotes an cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 3 to n C atoms, at least two of which are bonded to each other by a double bond.
• C 3 _ 7 -cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl cycloheptadienyl and cycloheptatrienyl.
• aryl denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated.
• Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl. More preferably the term "aryl” as used herein, either alone or in combination with another radical, denotes phenyl or naphthyl, most preferably phenyl.
• ArylCi- ⁇ alkyl means a Ci_ 6 alkyl having at least one alkyl hydrogen atom replaced with an aryl moiety, such as -CH 2 -phenyl, -CH 2 -CH 2 -phenyl and the like.
• heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, oxadiazolyl, thiadiazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl.
• heterocycles may be attached via any heteroatom or carbon atom.
• Heterocycles include heteroaryls as defined above.
• heterocycles also include (but are not limited to) morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperizinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
• prodrugs are also included within the context of this invention.
• Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient.
• Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
• Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or acid groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or acid groups.
• representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I).
• esters may be employed, such as methyl esters, ethyl esters, and the like.
• stereoisomers the compounds of structure (I) may have chiral centers and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
• the compounds of the present invention may exist in a continum of solid states ranging from fully amorphous to fully crystalline. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention. In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents.
• solvate is used herein to describe a molecular complex comprising a compound of the present invention and one or more pharmaceutically acceptable solvent molecules. Such solvates are similarly included within the scope of this invention.
• the present invention also includes all pharmaceutically acceptable isotopically labeled compounds of structure (I) where on or more atoms are replaced by atoms having the same atomic number but a different atomic mass.
• examples include 2 H and 3 H for hydrogen, 11 C, 13 C and 14 C for carbon, 36 Cl for chlorine, 18 F for fluorine, 123 I and 125 I for iodine, 13 N and 15 N for nitrogen, and 35 S for sulfur.
• Compounds of the present invention include compounds of structure (I) as defined, including all polymorphs, prodrugs, isomers (including optical, geometric and tautomeric), salts, solvates and isotopes thereof.
• GPRl 19 agonists of the present invention may be used to treat subjects with a variety of diseases and conditions.
• GPRl 19 agonists of the present invention may be used to treat diseases and conditions which are mediated by the modulating the activity of GPRl 19.
• GPRl 19 agonists of the present invention may be used to treat diabetes, in particular type 2 diabetes mellitus or type 1 diabetes mellitus.
• GPRl 19 agonists of the present invention may be used to treat obesity.
• GPRl 19 agonists of the present invention may be used to treat type 1 diabetes, type 2 diabetes, insufficient glycemic control, insulin resistence, hyperglycemia, hyper lipidemia, hypercholesterolemia, dyslipidemia, syndrom X, metabolic syndrom, obesity, hypertension, chronic systemic inflammation, retinopahtie, neuropathie, nephropathie, atherosclerosis, endothelial dysfunction and bone related conditions such as osteoporosis, rheumatoid arthritis or osteoarthritis.
• GPRl 19 agonists of the present invention may be used to treat, slow, delay or reverse a progression of impaired glucose tolerance, impaired fasting blood, glucose insulin resistance and/or metabolic syndrom to type 2 diabetes.
• GPRl 19 agonists of the present invention may be used to treat or improve the glycemic control and/ or to reduce fasting blood glucose, postprandial glucose and/or of glycosylated hemoglobin HbAl c.
• GPRl 19 agonists of the present invention may be used to prevent, slow progression of, delay or treat of a condition or disorder selected from the group consisting of complications of diabetes mellitus, for example cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis.
• complications of diabetes mellitus for example cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis.
• GPRl 19 agonists of the present invention may be used to reduce body weight and/or body fat, or prevent an increase in body weight and/or body fat, or to facilitate a reduction in body weight and/or body fat
• GPRl 19 agonists of the present invention may be used to prevent, slow, delay or treat the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or to improve and/or restore the functionality of pancreatic beta cells and/or restore the functionality of pancreatic insulin secretion
• GPRl 19 agonists of the present invention may be used to maintain and/or improve the insulin sensitivity and/or to treat or prevent hyperinsulinemia and/or insulin resistance
• the compounds of the present invention may be useful in combination with one or more additional therapeutic agents, particularly therapeutic agents suitable for the treatment and/or prevention of the conditions and diseases presented previously.
• Additional therapeutic agents which may be suitable for combination with one or more compounds of the present invention which include insulin and insulin analogs, sulfonylureas (such as glibenclamide, glimepiride, tolbutamide), meglitinides (such as nateglinide, mitiglinide), biguanides (especially metformin), PPAR modulators including the thiazolidinediones (such as pioglitazone, rivoglitazone), DPP-4 inhibitors (such as alogliptin, linagliptin), alpha-glucosidase inhibitors (such as acarbose, miglitol, voglibose), GLP-I analogs (such as exenitide, liraglutide), SGLT-2 inhibitors (such as dapagliflo
• compositions comprising one or more GPRl 19 receptor agonists are disclosed.
• the compounds of the present invention may be formulated as pharmaceutical compositions.
• Pharmaceutical compositions of the present invention comprise a GPRl 19 receptor agonist of the present invention and a pharmaceutically acceptable carrier and/or diluent.
• the GPRl 19 receptor agonist is present in the composition in an amount which is effective to treat a particular disorder —that is, in an amount sufficient to achieve GPRl 19 receptor agonist activity, and preferably with acceptable toxicity to the patient.
• compositions formulated as liquid solutions include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives.
• the compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a GPRl 19 receptor agonist, diluents, dispersing and surface active agents, binders, and lubricants.
• GPRl 19 receptor agonist e.g., a GPRl 19 receptor agonist, diluents, dispersing and surface active agents, binders, and lubricants.
• One skilled in this art may further formulate the GPRl 19 receptor agonist in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.
• the present invention provides a method for treating various diseases and/or conditions as described hereinbefore and hereinafter, in particular obesity and diabetes and related conditions as discussed above.
• Such methods include administering of a compound of the present invention to a patient in an amount sufficient to treat the condition.
• "treat” includes prophylactic administration.
• Such methods include systemic administration of a GPRl 19 receptor agonist of this invention, preferably in the form of a pharmaceutical composition as discussed above.
• systemic administration includes oral and parenteral methods of administration.
• the dose range of the compounds of general formula (I) applicable per day is usually from 0.001 to 10 mg, preferably from 0.01 to 8 mg per kg body weight of the patient.
• Each dosage unit may conveniently contain from 0.1 to 1000 mg of a compound according to the invention.
• the actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon patient's unique condition.
• suitable pharmaceutical compositions of GPRl 19 receptor agonists include powders, granules, pills, tablets, lozenges, chews, gels, and capsules as well as liquids, syrups, suspensions, elixirs, and emulsions.
• the compounds of the invention may also be used in fast dissolving, fast disintegrating dosage forms.
• These compositions may also include anti-oxidants, flavorants, preservatives, suspending, thickening and emulsifying agents, colorants, flavoring agents and other pharmaceutically acceptable additives.
• Formulations for oral administration may be formulated to be immediate release or modified release, where modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release.
• parenteral administration the compounds of the present invention are administered directly into the blood stream, into muscle, or into an internal organ via an intravenous, intraarterial, intraperitoneal, intramusclar, subcutaneous or other injection or infusion.
• Parenteral formulations may be prepared in aqueous injection solutions which may contain, in addition to the GPRl 19 receptor agonist, buffers, antioxidants, bacteriostats, salts, carbohydrates, and other additives commonly employed in such solutions.
• Parenteral administrations may be immediate release or modified release (such as an injected or implanted depot).
• Compounds of the present invention may also be administered topically, (intra)dermally, or transdermally to the skin or mucosa.
• Typical formulations include gels, hydrogels, lotions, solutions, creams, ointments, dressings, foams, skin patches, wafers, implants and microemulsions.
• Compounds of the present invention may also be administered via inhalation or intanasal administration, such as with a dry powder, an aerosol spray or as drops. Additional routes of administration for compounds of the present invention include intravaginal and rectal (by means of a suppository, pessary or enema), and ocular and aural.
• GPRl 19 receptor agonists of this invention may be synthesized and assayed by the general methods disclosed in the following Examples.
• Agilent 1100 series equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (APCI);
• HPLC column Phenomenex Synergi: MAX-RP, 2.0 x 50 mm column;
• HPLC gradient 1.0 mL/minute, from 10% acetonitrile in water to 90% acetonitrile in water in 2.5 minutes, maintaining 90% for 1 minute. Both acetonitrile and water have 0.025% TFA.
• Agilent 1100 series equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (APCI);
• HPLC column Phenomenex Synergi-Max RP, 2.0 x 50 mm column; HPLC gradient: 1.0 mL/minute, from 5% acetonitrile in water to 95% acetonitrile in water in 13.5 minutes, maintaining 95% for 2 minute. Both acetonitrile and water have 0.025% TFA.
• Agilent 1100 series equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (electrospray);
• HPLC column XTerra MS, Ci 8 , 5 ⁇ , 3.0 x 250 mm column; HPLC gradient: 1.0 mL/minute, from 10% acetonitrile in water to 90% acetonitrile in water in 46 minutes, jump to 99% acetonitrile and maintain 99% acetonitrile for 8.04 minutes. Both acetonitrile and water have 0.025% TFA.
• Agilent 1100 series equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (electrospray);
• HPLC column Waters XBridge 5 ⁇ Cl 8 11OA, 3.0 x 100 mm HPLC gradient: 1.5 mL/min, from 5% acetonitrile in water to 90% acetonitrile in water in 9.86 minutes, from 90% acetonitrile in water to 95% acetonitrile in water in 0.1 minutes, hold at 95% for 1.19 minutes. Both acetonitrile and water have 0.04% NH 4 OH
• HPLC column Phenomenex Gemini 5 ⁇ C18 HOA, 3.0 x 150 mm
• HPLC gradient 1.5 mL/min, from 5% acetonitrile in water to 90% acetonitrile in water in 9.86 minutes, from 90% acetonitrile in water to 95% acetonitrile in water in 0.1 minutes, hold at 95% for 1.19 minutes. Both acetonitrile and water have 0.04% NH 4 OH
• Agilent 1100 series equipped with an auto-sampler, an UV detector (220 nM and 254 nM), a MS detector (APCI);
• HPLC column Phenomenex Synergi-Max RP, 2.0 x 50 mm column; HPLC gradient: from 5% B to 95% B in A in 6.43 minutes, 9.17 minutes total run time.
• HPLC column BHK ODS-O/B, 5 ⁇ , 30x75 mm HPLC gradient: 35 mL/minute, 10% acetonitrile in water to 100% acetonitrile in 7 minutes, maintaining 100% acetonitrile for 3 minutes, with 0.025% TFA.
• Dionex P680A and P680P pumps Dionex PAD 100 photodiode array detector, Jasco CD 2095 plus chiral detector, Gilson 215 liquid handler.
• Analytical Columns are 0.46 x 25 cm, 5 ⁇ m; preparative columns are 2 x 25 cm, 5 ⁇ m.
• Step IA 2.3-Dihvdro-lH-pyrrolor3.2-blpyridine (1-1)
• borane tetrahydrofuran complex 60 mL of a 1 M solution, 6 eq
• the mixture was heated at reflux for 5h.
• water was added slowly and the solution was extracted with ethyl acetate twice.
• the combined extracts were washed with a saturated solution of sodium bicarbonate, dried over sodium sulfate and evaporated.
• the residue was purified on silica gel (eluent: 15% methanol in DCM) to give 0.17 g of 2,3-dihydro-lH-pyrrolo[3,2- b]pyridine 1-1.
• Step 2A 4-Hydroxy-piperidine-l-carboxylic acid isopropyl ester (2a)
• Step 2B 4-(6-Chloro-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid isopropyl ester
• Step 2C 4-[6-(2,3-Dihydro-pyrrolo[3,2-blpyridin- 1 -yl)-pyrimidin-4-yloxy "
• 2b 100 mg, 0.33 mmol
• potassium tert-butoxide 0.1 g, 2.7 eq
• Step 3 A 4-(6-Chloro-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid tert-butyl ester (3a)
• Step 3B 4-[6-(5-Bromo-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• Step 3C 4 4-[6-(5-Bromo-2,3-dihydro-indol-l-yl)-pyrimidin-4-yloxyl-piperidine-l- carboxylic acid tert-butyl ester (3-1)
• Step 4A 4-
• 5- methanesulfonyl-2,3-dihydro-lH-indole (0.63 g , 1 eq).
• 3a (1 g, 3.19 mmol) was added.
• the resulting mixture was heated up to 80 0 C for 18h.
• Step 4B 5-Methanesulfonyl-l-[6-(piperidin-4-yloxy)-pyrimidin-4-yll-2,3-dihydro-lH- indole (4b)
• Step 4C 4-r6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• Step 5 A 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid cyclobutyl ester (5-1)
• Step 6A l-(6-Chloro-pyrimidin-4-yl)-5-methanesulfonyl-2,3-dihydro-lH-indole (6a)
• Step 6B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-ylamino "
• Step 6C [6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yll-piperidin-4-yl- amine (6c)
• Step 6D 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-ylaminol- piperidine-1-carboxylic acid isopropyl ester (6-1)
• Step 7A (l-Benzyl-piperidin-4-yl)-carbamic acid tert-butyl ester (7a)
• Step 7B (l-Benzyl-piperidin-4-yl)-methyl-amine (7b).
• Step 7C (l-Benzyl-piperidin-4-yl)-[6-(5-methanesulfonyl-2,3-dihydro-indol-l-yl)- pyrimidin-4-yll -amine (7c)
• Step 7D [6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yll-piperidin-4-yl- amine (7d)
• Step 7E 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-ylaminol- piperidine-1-carboxylic acid isopropyl ester (7-1).
• Step 8 A 4-(6-Chloro-5-methoxy-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid isopropyl ester (8a)
• Step 8B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-5-methoxy-pyrimidin-4- yloxyl-piperidine-1-carboxylic acid isopropyl ester (8-1)
• Step 9A 4-(6-Chloro-5-methyl-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid tert- butyl ester (9a)
• Step 9B 4-(6-Chloro-5-methyl-pyrimidin-4-yloxy)-piperidine-l -carboxylic acid isopropyl ester (9b).
• 9a was dissolved in a 4 M solution of HCl in dioxane (60 mL). The solution was stirred at room temperature for 3h and the solvent was removed. The residue was taken up in 200 mL of DCM and 40 mL of toluene and cooled to 0 0 C. Isopropyl chloroformate (60 mL of a 1 M solution in toluene, 1.2 eq) and diisopropylethylamine (24 mL) were added.
• Step 9C 4-[5-Methyl-6-(5-nitro-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• Step IQA 4-(2-Chloro-pyridin-4-yloxy)-piperidine-l-carboxylic acid isopropyl ester (IQa) and 4-(4-Chloro-pyridin-2-yloxy)-piperidine-l-carboxylic acid isopropyl ester (IQb)
• 2,4-Dichloropyridine (0.52 g, 3.5 mmol) in 2 mL of DMF was added to a suspension of sodium hydride (60% in oil, 0.16 g, 3 eq) and 2a (0.55 g, 3 mmol) in 8 mL of DMF.
• the mixture was heated at 90 0 C.
• the mixture was allowed to cool to room temperature, water was added to quench the excess sodium hydride and the solution was extracted with ethyl acetate twice, washed with a saturated solution of sodium bicarbonate, dried and evaporated.
• the crude material was purified on silica gel (eluent: 20% then 50% of ethyl acetate in hexane) to give 10a and 10b (0.55 g of the more polar product and 84 mg of the less polar product).
• Step IQB 4-[4-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyridin-2-yloxyl-piperidine- 1-carboxylic acid isopropyl ester (10-2) and 4-[2-(5-Methanesulfonyl-2,3-dihydro-indol-l- yl)-pyridin-2-yloxy
• Step 1 IA l-(4-Chloro-[1.3.51triazin-2-ylV5-methanesulfonyl-2.3-dihvdro-lH-indole (Ha)
• Step 1 IB 4-[4-(5-Methanesulfonyl-2.3-dihvdro-indol-l-ylV[1.3.51triazin-2-yloxy1- piperidine-1-carboxylic acid tert-butyl ester (11-1)
• Step 12A 4-(2-Chloro-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid isopropyl ester (12a) and 4-(4-Chloro-pyrimidin-2-yloxy)-piperidine-l-carboxylic acid isopropyl ester (12b)
• 2,4-Dichloro-pyrimidine (2.3 g) was added at 0 0 C to a solution of 2a (3.1 g, 1 eq) and potassium tert-butoxide (1.74 g, 1 eq) in 20 mL of THF. The mixture was stirred for Ih then quenched with water. The product was extracted with ethyl acetate twice, washed with water and dried over sodium sulfate. The solvent was evaporated and the residue was taken up with methanol and dichloromethane and purified on silica gel (eluent: 20% ethyl acetate in hexane) to give a mixture of 12a and 12b. This was used directly on the next step.
• Step 12B 4-[2-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid isopropyl ester (12-1) and 4-
• Step 13 A 4-[5-Fluoro-6-(5-methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• Step 14A 4-(6-Chloro-2-methyl-pyrimidin-4-yloxy)-piperidine-l-carboxylic acid isopropyl ester (14a)
• Step 14B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-2-methyl-pyrimidin-4- yloxyl-piperidine-1-carboxylic acid isopropyl ester (14-1)
• Step 15 A 3-
• - azetidine-1-carboxylic acid tert-butyl ester (15-1) To a suspension of NaH (30 mg, 0.75 mmol) in 1 mL of DMF, was added 3- hydroxy-azetidine-1-carboxylic acid tert-butyl ester (74 mg, 0.43 mmol) and the mixture was stirred at room temperature for 30 minutes. 6a (0.1 g, 0.32 mmol) was added and the mixture was heated at 80 0 C for 2 Ih.
• Step 16A 4- ⁇ [6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yll-methyl- aminol-piperidine-l-carboxylic acid tert-butyl ester (16-1)
• Step 17A 4-(6-Chloro-pyrimidin-4-ylamino)-piperidine-l-carboxylic acid tert-butyl ester (17a)
• Step 17B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-ylamino "
• 5- methanesulfonyl-2,3-dihydro-lH-indole (1.9 g, 9.63 mmol) was added and the mixture was stirred at room temperature for 30 minutes.
• 17a (3.09 g, 9.88 mmol) was added in DMF and the mixture was heated at 85 0 C for 17h. After cooling to room temperature, brine was added (200 mL) and the mixture was extracted with DCM (200 mL then 3 x 500 mL). The combined extracts were washed with brine (3 x 100 mL), dried, filtered and evaporated. The residue was purified by flash chromatography (eluent : 25 to 100% EtOAc in hexane with 0.1% triethylamine) to afford 2.83 g (62 %) of 17b.
• Step 17C 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-ylaminol- piperidine-1-carboxylic acid isopropyl ester (17-1).
• Step 18A 4-tert-Butoxycarbonylamino-piperidine-l -carboxylic acid isopropyl ester (18a)
• Step 18B 4-Amino-piperidine-l -carboxylic acid isopropyl ester (18b) To a solution of 18a (3.26 g, 11.37 mmol) in 10 mL of DCM, was added TFA (5 mL, 64.9 mmol). The mixture was stirred at room temperature for 2h and the solvent were evaporated. The residue was dissolved in DCM and a saturated solution of NaHCOs and IN NaOH were added until pH was 8. The layers were separated and the aqueous layer was extracted with 3:1 DCM:IPA (3 x 40 mL). The organic extracts were combined, dried, filtered and evaporated to afford 1.89 g (89%) of 18b.
• Step 18C 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-ylaminol- piperidine-1-carboxylic acid isopropyl ester (18-1)
• Step 19A 2,3-Dihydro-lH-indole-5-carboxylic acid methyl ester (19a)
• Step 19B l-[6-(l-tert-Butoxycarbonyl-piperidin-4-yloxy)-pyrimidin-4-yll-2,3-dihydro- lH-indole-5-carboxylic acid (19b)
• Step 19C l-[6-(l-Isopropoxycarbonyl-piperidm-4-yloxy)-pyrimidin-4-yl]-23-dihydro- lH-indole-5-carboxylic acid (19c)
• Step 19D l-[6-(l-Isopropoxycarbonyl-piperidin-4-yloxy)-pyrimidin-4-yll-2,3-dihydro- lH-indole-5-carboxylic acid (19-1)
• Step 2OB 4-[6-(5-Chloro-2,3-dihydro-pyrrolo[3,2-blpyridin-l-yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid tert-butyl ester (20-1)
• Step 2 IA 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• Step 2 IB 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid pyrrolidin-3-yl ester (21b)
• 21a was dissolved in 2.5 mL of DCM and 2.5 mL of TFA was added. The mixture was stirred at room temperature for 2h then evaporated and the crude material was dissolved in DCM, washed with saturated NaHCO 3 (3 x 10 mL), dried, filtered and evaporated to afford 21b.
• Step 21 C 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxy "
• 2-Fluoro-benzaldehyde (11 ⁇ L, 0.1 mmol) was dissolved in 1 mL of DCE with
• Step 22A 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid l-tert-butoxycarbonyl-azetidin-3-yl ester (22a)
• Step 22B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid azetidin-3-yl ester (22-1)
• Step 23 A 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid l-benzyl-pyrrolidin-3-yl ester (23a)
• Step 23B 4-[6-(5-Methanesulfonyl-2,3-dihydro-indol-l-yl)-pyrimidin-4-yloxyl- piperidine-1-carboxylic acid pyrrolidin-3-yl ester (23-1)
• EXAMPLE 24 4-[5-CYANO-2-(5-METHANESULFONYL-2,3-DIHYDRO-INDOL-1-YL)-PYRIDIN-4-YLOXY]-
• Step 24A 4-[5-Bromo-2-(5-methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyridin-4-yloxyl- piperidine-1-carboxylic acid isopropyl ester (24a) and 4-[3-Bromo-4-(5-methanesulfonyl- 2,3-dihydro-indol-l-yl)-pyridin-2-yloxyl-piperidine-l-carboxylic acid isopropyl ester (24b) To a solution of 10a (0.15 g, 0.5 mmol) in 2 rnL of acetonitrile, was added bromine
• Step 24B 4-[5-Cyano-2-(5-methanesulfonyl-2,3-dihydro-indol- 1 -yl)-pyridin-4-yloxy "
• HEK293 cells stably expressing a mutant form of the human GPRl 19 receptor were grown to 50-70% confluency in cell culture media (DMEM, 10% heat inactivated Fetal Bovine Serum, 50 I.U./mL penicillin, 50 ⁇ g/mL streptomycin, 10 mM HEPES, 20 ⁇ g/mL G418 Sulfate).
• Detection Buffer 5OmM HEPES, 1OmM calcium chloride, 0.35% Triton X-100, 1 mg/mL BSA
• Detection Buffer containing europium- labeled cAMP tracer complex was added to all wells and allowed to react for lhour at room temperature. After 1 hour, bound europium-labeled cAMP tracer was measured using a Perkin Elmer ViewLux. The quantity of cAMP generated in each well was derived from a standard curve.
• the efficacy is provided at a single concentration (lO ⁇ M) yielding % stimulation values.
• Rat pancretic islets are isolated and allowed to recover overnight in RPMI cell culture media (10% FBS, 50 I.U./mL penicillin, 50 ⁇ g/mL streptomycin, 1OmM HEPES) containing 11 mM Glucose. After incubating overnight at 37 0 C and 5% CO 2 /95% air, the islets were thoroughly washed 5x in Ix Krebes Ringes HEPES buffer (118mM NaCl, 4.8 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 20 mM HEPES, 0.1% BSA, adjusted to a pH of 7.4 with NaOH) with 5 mM Glucose. Islets were allowed to preincubate for 30 minutes in Ix KRH with 5 mM Glucose at 37 0 C before assay initiation.
• RPMI cell culture media 10% FBS, 50 I.U./mL penicillin, 50 ⁇
• Test compounds are diluted in Ix KRH containing an appropriate concentration of glucose so that at the initiation of the islet assay the final glucose concentration was 8.3 mM.
• compound solutions were added to islets in wells to give a final volume of 2.4mL of IxKRH with 8.3 mM glucose and allowed to incubate at 37 0 C. Aliquots of supernatant were removed at various times points and were assayed for insulin using a commercially available insulin RIA kit (Linco Research Labs).
• the islets are removed from the 24 well plates into separate 1.5mL epindorf tubes containing ImL of Ix KRH with no glucose and then placed on ice. Islets are allowed to settle for 5 min before the supernatant is removed and 300 ⁇ L of acid/ethanol is added to each tubes. Following brief sonication tubes are stored at -20 0 C for at least 24 hours before assayed for total insulin content. For quantification purposes, the amount of stimulated insulin secretion is expressed as a fraction of total insulin in the assay well.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Pain & Pain Management (AREA)
• Emergency Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Ophthalmology & Optometry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42712012

Family Applications (1)

Country Status (6)

Cited By (11)

Families Citing this family (3)

Citations (1)

Family Cites Families (112)

• 2010
  • 2010-06-23 US US12/821,219 patent/US8481731B2/en active Active
  • 2010-06-23 WO PCT/EP2010/058874 patent/WO2010149685A1/en not_active Ceased
  • 2010-06-23 TW TW099120497A patent/TW201113269A/zh unknown
  • 2010-06-23 EP EP10725783A patent/EP2445901A1/en not_active Withdrawn
  • 2010-06-23 JP JP2012516707A patent/JP2012530758A/ja active Pending
  • 2010-06-23 AR ARP100102226A patent/AR077214A1/es unknown

Patent Citations (2)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events